USE OF THE RESULTS. OF THE ACTION BY THE AGENCY AND/OR THE UNION
USE OF THE RESULTS. I.11.1 Any results or rights thereon, including copyright and other intellectual or industrial property rights, obtained in performance of the Contract, shall be owned solely by the European Union, which may use, publish, assign or transfer them as it sees fit, without geographical or other limitation, except where industrial or intellectual property rights exist prior to the Contract being entered into.
USE OF THE RESULTS. [Not applicable.]
USE OF THE RESULTS. Both institutions have the right to use the results and the dissertation for the purposes of teaching and research activities. Separate agreements shall be written for works that may lead to patents.
USE OF THE RESULTS. For the purpose of Article II.3.2 of the Agreement, the use of the results of the action shall include – the right, for the Agency and/or the Commission, to request that the beneficiaries make the said results available to the public via the European Commission-supported information platform «EVE», available at the following Internet address: xxxx://xx.xxxxxx.xx/eve/
USE OF THE RESULTS. For implementation of the Project The default situation is that Parties grant one another access to their Results on a non-exclusive, royalty free basis for the purpose and the term of the Consortium Agreement. However, Parties are free to negotiate different terms and conditions or even draw up a separate licence agreement. . In most cases it will not be allowed to grant a sub-licence of another Party’s Results to a third party. Parties can decide to qualify each other’s Affiliates as not being a third party. For exploitation of Results If a Party wishes to have access to another Parties Results for Dissemination and Implementation purposes, this will need to be negotiated separately. The Consortium Agreement may include a provision that Parties will negotiate such a licence on fair and reasonable conditions.
USE OF THE RESULTS. Each Party may freely use the property rights it holds alone in accordance with Article 20.1. For the sake of clarity, the Research project leader of a Research Project understands that the Results does not comprehend Patients’ Data. Data Access The Registry Host provides secured access to the system to authorized Users of the Registry and Recipients. The Registry Host ensures that all the Registry Data is stored on a secured server with appropriate level of encryption as defined in Appendix 4. The Recipients and Users of the Registry will access to the Registry Data in accordance with the Data Access Policy attached in Appendix 6 (the “Data Access Policy”). The Parties shall reduce access to Registry Data to an absolute minimum, on the basis of necessity and respect the roles assigns to the Recipients and Users of the Registry. Users of the Registry will have access to their own Patients Data through the Database. The HCP agrees that HCP Data may be shared with Recipients, in Aggregated or Pseudonymised format, according to the conditions defined in the Data Access Policy. The HCP is liable for any access to the Registry Data or to the Database by its Users or through its User’s access accounts or credentials. The HCP acknowledges and agrees to notify the Coordinator promptly if any of its Users leave the HCP to allow the Coordinator to revoke related access rights at the effective date of such change. Such notification should be made at the following address: xxxxxxxx@xxx-xxxx-xxx.xx.
USE OF THE RESULTS. [NOT APPLICABLE]
USE OF THE RESULTS. With regard to the goals of the “Fund” and in respect of any collaborative relationships or partnerships, howsoever arising between the Beneficiary and overseas corporations, it remains expressly understood that: • up to the date of signing of the final declaration, the Beneficiary undertakes to refrain from transferring the results and know-how derived from the funded research project, in any form whatsoever, in all or in part, to overseas corporations or undertakings controlled by overseas corporate groups (including those that are shareholders in the Beneficiary), except against receipt of due consideration for the same; • the Beneficiary undertakes to develop industrial applications of the results of the research project covered hereunder, prioritising for such purpose, facilities located within Italy. By express agreement between the parties, therefore, in the case of the Beneficiary’s failure to fulfil the foregoing obligations in whole or in part, the Bank [*] Indicates that certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. shall be entitled to deem this agreement terminated by right, entailing the consequences mentioned in Article 13 below, by giving [*] thereof to the Beneficiary.
USE OF THE RESULTS. With regard to the goals of the "Fund" and in respect of any collaborative relationships or partnerships, howsoever arising between the Beneficiary and overseas corporations, it remains expressly understood that: • up to the date of [*], the Beneficiary undertakes to refrain from transferring the [*] and [*] derived from the [*] project, in any form whatsoever, in all or in part, to [*] or undertakings controlled by [*] (including those that are [*]), except against receipt of due consideration for the same; • the Beneficiary undertakes to develop industrial applications of the results of the research project covered hereunder, prioritising for such purpose, facilities located within Italy.
